The biotech sector is expanding due to innovations and robust demand. In addition, as the biotech sector enjoys inelastic demand for its products and services, it remains relatively stable in the face of economic uncertainty.
So, investors looking for quality biotech stocks can consider buying Gilead Sciences, Inc. (GILD). However, I think it could be wise to wait for a better entry point in Moderna, Inc. (MRNA), for reasons discussed throughout this article.
